March 13, 2022
Prevatex has signed a supply and licence agreement with Ipromea. Prevatex has agreed to sell product and has a granted a licence to Ipromea to use Prevatex IP for research, development and commercialisation of the Ipromea products in territory, limited to Australia and parts of Asia.
Ipromea agrees to exclusive use the product in development and commercialisation of companion animal gut microbiome products in the territory.
In consideration of the rights granted, Ipromea agrees to pay Prevatex a licence fee which includes a share of nett revenue.